arrow
G

Georgina V. Long

the university of sydney
H指数:169
被引数:17.2万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial

瑞利替尼单抗联合纳武利尤单抗对比纳武利尤单抗治疗晚期黑色素瘤:RELATIVITY-047 III期试验5年生存率及生物标志物分析

2026-10-240
OAAI
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

原发性黑色素瘤假阴性诊断患者的生命损失年数。一项涉及9063例患者、为期28年的德国中央恶性黑色素瘤登记研究的回顾性研究

2026-07-020
OAAI
CSF1R-dependent CD169-positive macrophages locally constrain melanoma growth in the skin

CSF1R依赖的CD169阳性巨噬细胞在皮肤中局部抑制黑色素瘤生长

2026-05-011
OA
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

黑色素瘤的新辅助治疗ipilimumab联合nivolumab: 来自2期PRADO试验的5年生存率和生物标志物分析

2026-01-280
PRE
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort

病理反应新辅助评分的更新的全肿瘤指南: SITC和INMC的联合努力

2025-11-040
PRE
Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma.

在临床上可检测的III期黑色素瘤中,新辅助免疫治疗后,通过减少肿瘤床检查,病理反应计算评估仍然准确。

2025-11-010
PRE
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

撤稿说明:sFRP2在衰老微环境中驱动黑色素瘤转移和疗法抵抗

Nature
IF48.5
2025-10-290
OAAI
Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1–5 extracranial melanoma oligometastases (AXIOM)

AXIOM研究:一项关于1-5个颅内外黑色素瘤寡转移患者中,同步立体定向体部放射治疗联合免疫治疗与单纯免疫治疗对比的随机II期试验研究方案

2025-10-230
OAAI
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

辅助性尼沃鲁单抗和雷拉利单抗在III/IV期黑色素瘤中的应用:随机III期RELATIVITY-098试验

2025-10-180
OAAI
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma

国际调查:III期黑色素瘤新辅助全身治疗后行哨兵淋巴结手术的证据

2025-10-140
OA
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study

妊娠期晚期黑色素瘤:一项回顾性、多中心、基于注册研究的建议

2025-10-070
OAAI
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma

III期黑色素瘤患者尽管对术前ipiLimumab联合nivolumab治疗表现出病理学反应,但疾病仍复发时的临床、病理及分子特征

2025-09-300
OA
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

新辅助PD-1和LAG-3靶向双特异性抗体与其他免疫检查点抑制剂联合治疗可切除黑色素瘤:随机Ib/II期Morpheus-Melanoma试验

2025-09-240
OAAI
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

III期黑色素瘤辅助治疗中的动态复发风险预测工具

2025-09-120
PRE